Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

A panelist discusses how a large propensity score–matched analysis of 1300 patients aged 60-75 found similar all-cause ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Johnson & Johnson stands second among the most ...

ImCheck Therapeutics receives EMA Orphan Drug Designation for ICT01 for treatment for acute myeloid leukemia: Marseille, France Thursday, July 24, 2025, 15:00 Hrs [IST] ImCheck Th ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has ...

MADRID and CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in ...

DelveInsight’s, “ Small Lymphocytic Lymphoma Pipeline Insight, 2025 ” report provides comprehensive insights about 80+ ...

Haematological diseases are pathological conditions primarily affecting the blood or blood-producing organs. This group of disorders includes, but is not limited to, various types of anaemia ...